Study analysis · Journal of Lipid Research · 2012
Niacin slashes liver fat by 47% – but it also spikes your blood sugar and insulin. Is it worth the trade-off?
Taking high-dose niacin for 23 weeks reduced liver fat by nearly half in people with high triglycerides, but it also raised blood sugar and insulin, potentially worsening diabetes risk.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
Imagine a group of 39 kids all get a new video game, and after playing for a while, their grades go up. We don't know if the game helped or if they studied harder. This study is like that: everyone got the same medicine (niacin), and we saw some improvements, but we can't be sure the medicine caused it because there was no group that didn't get it to compare.
What’s the bottom line?
Niacin, a B vitamin, lowered liver fat in Chinese patients with high triglycerides but also raised blood sugar and insulin.
How strong is this study?
This study was done carefully – they used a special machine to measure liver fat – but it only had 39 people and no comparison group. Also, the people lost a little weight during the study, which might have affected the results. So it's like a good first guess, but we need a bigger, better study to trust the answer.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
17 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=39)+3.5/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Uncontrolled before-after design without a control group; small sample size (n=39); confounding by weight loss (mean -1.17 kg); no randomization or blinding; genetic subgroup analysis not pre-specified.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information provided in the available text.
The study uses a branded drug (Niaspan from Abbott Laboratories) but no industry funding or author conflicts are disclosed. Authors are from academic institutions.
Key takeaways
- 01
Liver fat decreased by about 47% on average, and triglycerides by 35%.
- 02
The effect is big, but weight loss also occurred and may have contributed.
Surprising findings
- Niacin increased fasting free fatty acids by 48.2% and insulin by 31.8%, despite reducing liver fat and triglycerides.Conventional wisdom says niacin lowers FFA by blocking lipolysis, but chronic treatment causes a rebound that may worsen insulin resistance. This contradicts the expected benefit on metabolic health.
- The DGAT2 variant allele carriers had a much smaller liver fat reduction despite similar changes in triglycerides and body weight.It shows the liver fat effect is at least partly independent of the triglyceride-lowering effect, and that genetics play a major role in drug response – something not typically considered in clinical practice.
Practical takeaways
If you have high triglycerides and fatty liver, do not start high-dose niacin without consulting a doctor – it may raise blood sugar and insulin.
This was a small, uncontrolled pilot study in Chinese patients. Results may not apply to other populations, and the long-term risk/benefit is unknown.
low confidenceFocus on weight loss first – even a 1.5% reduction in body weight was associated with a 58.6% liver fat drop in this study.
Weight loss was not randomized; it may have been partly due to participation in a clinical trial. Other studies show that 5-10% weight loss is more effective for NAFLD.
medium confidenceConsider genetic testing for DGAT2 variants if you’re prescribed niacin for liver fat – those with variant alleles may get little benefit.
These genetic tests are not widely available or clinically validated for this purpose. The finding needs replication.
low confidenceWhy this study matters
Massive liver fat reduction – but with a catch
In 39 Chinese patients with hypertriglyceridemia, 2g/day of extended-release niacin for 23 weeks led to a 47.2% relative reduction in liver fat and a 34.9% drop in triglycerides. However, fasting free fatty acids jumped 48.2%, insulin rose 31.8%, and blood sugar and HbA1c also increased significantly.
Most people think of niacin as a harmless vitamin, but this study shows it can improve fatty liver while paradoxically worsening metabolic health – a classic double-edged sword.
Your genes might blunt niacin's effect
Patients with two copies of the variant DGAT2 rs3060 allele experienced only a 1.5% absolute liver fat reduction compared to 8.2% in those with the common TT genotype – a 5-fold difference. The DGAT2 gene encodes a key enzyme in triglyceride synthesis that niacin is thought to inhibit.
Personalized medicine: this suggests that genetic testing could identify who benefits most from niacin for fatty liver, saving others from side effects without benefit.
Weight loss confounded the results
Patients lost an average of 1.17 kg (1.5% body weight) during the study. Those losing ≥1 kg had a 58.6% liver fat reduction vs. 35.3% in those gaining weight. Even after statistical adjustment, weight loss accounted for part of the effect.
Many people assume supplements work magic, but lifestyle changes (even small ones) often drive the results. This highlights the importance of rigorous controls in nutrition research.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Niacin, a B vitamin, lowered liver fat in Chinese patients with high triglycerides but also raised blood sugar and insulin.
Research results
Liver fat decreased by about 47% on average, and triglycerides by 35%.
What this means - more context
The effect is big, but weight loss also occurred and may have contributed.
To examine the effect of extended-release niacin on liver fat content in Chinese patients with dyslipidemia and whether common DGAT2 polymorphisms influence this effect.
In 39 Chinese hypertriglyceridemic patients, 23 weeks of niacin (2 g/day) was associated with a 47.2% relative reduction in liver fat content and a 34.9% reduction in plasma triglycerides, but also with increases in fasting free fatty acids (48.2%), insulin (31.8%), glucose, and glycated hemoglobin. Body weight decreased by 1.5% on average, and liver fat changes remained significant after adjustment. DGAT2 variant alleles were associated with smaller liver fat reductions.
Methods Used
39 Chinese patients with dyslipidemia (baseline liver fat 12.8%, triglycerides 3.30 mmol/l) were treated with extended-release niacin titrated to 2 g/day for 23 weeks. Liver fat content was measured by proton MR spectroscopy, visceral/subcutaneous fat by MRI, and DGAT2 rs3060 and rs10899116 polymorphisms were genotyped.
Main Finding
Extended-release niacin (2 g/day for 23 weeks) was associated with a 47.2% relative reduction in liver fat content (mean absolute change -6.1% after adjustment) and a 34.9% reduction in plasma triglycerides. However, niacin also increased fasting free fatty acids, insulin, glucose, and glycated hemoglobin. DGAT2 polymorphisms influenced the liver fat response.
Confidence Level
Moderate – pilot study with uncontrolled design, small sample, and potential confounding by weight loss. Authors call for larger randomized trials.
Study Flags
Red Flags
- •Uncontrolled design
- •Small sample size (39 patients)
- •Confounding by weight loss
Surprising Findings
Niacin increased fasting free fatty acids by 48.2% and insulin by 31.8%, despite reducing liver fat and triglycerides.
Conventional wisdom says niacin lowers FFA by blocking lipolysis, but chronic treatment causes a rebound that may worsen insulin resistance. This contradicts the expected benefit on metabolic health.
Practical Takeaways
If you have high triglycerides and fatty liver, do not start high-dose niacin without consulting a doctor – it may raise blood sugar and insulin.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
Imagine a group of 39 kids all get a new video game, and after playing for a while, their grades go up. We don't know if the game helped or if they studied harder. This study is like that: everyone got the same medicine (niacin), and we saw some improvements, but we can't be sure the medicine caused it because there was no group that didn't get it to compare.
Strengths
- Prospective design with pre-defined endpoints
- Objective liver fat measurement using proton MR spectroscopy
- Adjustment for confounders (age, gender, weight change)
Weaknesses
- No control group (uncontrolled before-after study)
- No randomization or blinding
- Small sample size (n=39) limits precision and subgroup analyses
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Niacin, a B vitamin, lowered liver fat in Chinese patients with high triglycerides but also raised blood sugar and insulin.
Research results
Liver fat decreased by about 47% on average, and triglycerides by 35%.
What this means - more context
The effect is big, but weight loss also occurred and may have contributed.
To examine the effect of extended-release niacin on liver fat content in Chinese patients with dyslipidemia and whether common DGAT2 polymorphisms influence this effect.
In 39 Chinese hypertriglyceridemic patients, 23 weeks of niacin (2 g/day) was associated with a 47.2% relative reduction in liver fat content and a 34.9% reduction in plasma triglycerides, but also with increases in fasting free fatty acids (48.2%), insulin (31.8%), glucose, and glycated hemoglobin. Body weight decreased by 1.5% on average, and liver fat changes remained significant after adjustment. DGAT2 variant alleles were associated with smaller liver fat reductions.
Methods Used
39 Chinese patients with dyslipidemia (baseline liver fat 12.8%, triglycerides 3.30 mmol/l) were treated with extended-release niacin titrated to 2 g/day for 23 weeks. Liver fat content was measured by proton MR spectroscopy, visceral/subcutaneous fat by MRI, and DGAT2 rs3060 and rs10899116 polymorphisms were genotyped.
Main Finding
Extended-release niacin (2 g/day for 23 weeks) was associated with a 47.2% relative reduction in liver fat content (mean absolute change -6.1% after adjustment) and a 34.9% reduction in plasma triglycerides. However, niacin also increased fasting free fatty acids, insulin, glucose, and glycated hemoglobin. DGAT2 polymorphisms influenced the liver fat response.
Confidence Level
Moderate – pilot study with uncontrolled design, small sample, and potential confounding by weight loss. Authors call for larger randomized trials.
Study Flags
Red Flags
- •Uncontrolled design
- •Small sample size (39 patients)
- •Confounding by weight loss
Surprising Findings
Niacin increased fasting free fatty acids by 48.2% and insulin by 31.8%, despite reducing liver fat and triglycerides.
Conventional wisdom says niacin lowers FFA by blocking lipolysis, but chronic treatment causes a rebound that may worsen insulin resistance. This contradicts the expected benefit on metabolic health.
Practical Takeaways
If you have high triglycerides and fatty liver, do not start high-dose niacin without consulting a doctor – it may raise blood sugar and insulin.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
Imagine a group of 39 kids all get a new video game, and after playing for a while, their grades go up. We don't know if the game helped or if they studied harder. This study is like that: everyone got the same medicine (niacin), and we saw some improvements, but we can't be sure the medicine caused it because there was no group that didn't get it to compare.
Strengths
- Prospective design with pre-defined endpoints
- Objective liver fat measurement using proton MR spectroscopy
- Adjustment for confounders (age, gender, weight change)
Weaknesses
- No control group (uncontrolled before-after study)
- No randomization or blinding
- Small sample size (n=39) limits precision and subgroup analyses
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was done carefully – they used a special machine to measure liver fat – but it only had 39 people and no comparison group. Also, the people lost a little weight during the study, which might have affected the results. So it's like a good first guess, but we need a bigger, better study to trust the answer.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
17 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=39)+3.5/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Uncontrolled before-after design without a control group; small sample size (n=39); confounding by weight loss (mean -1.17 kg); no randomization or blinding; genetic subgroup analysis not pre-specified.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information provided in the available text.
The study uses a branded drug (Niaspan from Abbott Laboratories) but no industry funding or author conflicts are disclosed. Authors are from academic institutions.